Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398632 · ClinicalTrials.gov registry record · Phase 4
Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction
A Phase 4 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00398632: Clinical Trial Phase 4 study, sponsored by Stanford University.
NCT00398632 is a Phase 4 study that was terminated before completion, run by Stanford University. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00398632, a Phase 4 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
Sexual dysfunction is a common side effect of selective serotonin reuptake inhibitors (SSRIs). The hypotheses of this study are that:1. subjects with major depression or dysthymia who are being treated with an SSRI and experiencing treatment-related sexual dysfunction will experience less sexual dysfunction if they are switched to duloxetine, and 2. they will experience either improved antidepressant response or no loss of antidepressant response.
Interventions
- DRUG Duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00398632
The ClinicalTrials.gov registry entry for NCT00398632 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Duloxetine is the first listed.
NCT00398632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00398632 about?
NCT00398632 is a clinical study titled "Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction". Sexual dysfunction is a common side effect of selective serotonin reuptake inhibitors (SSRIs). The hypotheses of this study are that:1. subjects with major depression or dysthymia who are being treated with an SSRI and experiencing treatment-related sexual dysfunction will experience less sexual dys...
What is the current status of trial NCT00398632?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2006-11. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00398632?
The interventions under investigation include: Duloxetine (DRUG).
Who is sponsoring clinical trial NCT00398632?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.